VitalSource™ GPO Industry Insights

Keeping your practice informed

Part B Billing For Biosimilar Products: Why the Modifier?

Since the 2010 passage of the Biologics Price Competition and Innovation Act, the FDA has worked to develop and implement an abbreviated licensure pathway for biological products proven to be interchangeable with a previously-licensed biological reference product.

Members Login

Become a member today